ESR1 and breast cancer: Triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype that lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for 10–20% of all breast cancers [1,2].